Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Wei Yu"'
Autor:
Hsu, Chia-Chi, Liao, Bin-Chi, Liao, Wei-Yu, Markovets, Aleksandra, Stetson, Daniel, Thress, Kenneth, Yang, James Chih-Hsin
Publikováno v:
In Journal of Thoracic Oncology January 2020 15(1):50-61
Autor:
Peters, Solange, Curioni-Fontecedro, Alessandra, Nechushtan, Hovav, Shih, Jin-Yuan, Liao, Wei-Yu, Gautschi, Oliver, Spataro, Vito, Unk, Mojca, Yang, James Chih-Hsin, Lorence, Robert M., Carrière, Philippe, Cseh, Agnieszka, Chang, Gee-Chen
Publikováno v:
In Journal of Thoracic Oncology December 2018 13(12):1897-1905
Autor:
Naoyuki Nogami, Mark A. Socinski, Delvys Rodriguez-Abreu, Federico Cappuzzo, Makoto Nishio, Daniil Stroyakovskiy, Anthony Lee, Gene Grant Finley, Geetha Shankar, Tony Mok, Christian Thomas, Robert M. Jotte, Ilze Bara, Shelley Coleman, Fabrice Barlesi, David Merritt, Denis Moro-Sibilot, Wei Yu, Francisco Orlandi, Darren Wan-Teck Lim, Martin Reck, Liza C. Villaruz, Joachim G.J.V. Aerts
Publikováno v:
Journal of Thoracic Oncology, 17(2), 309-323. International Association for the Study of Lung Cancer
JOURNAL OF THORACIC ONCOLOGY
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (2), pp.309-323. ⟨10.1016/j.jtho.2021.09.014⟩
JOURNAL OF THORACIC ONCOLOGY
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (2), pp.309-323. ⟨10.1016/j.jtho.2021.09.014⟩
Introduction: Final overall survival (OS) analyses are presented for EGFR mutations and liver or brain metastases subgroups in the phase 3 IMpower150 study (NCT02366143) evaluating atezolizumab plus bevacizumab plus carboplatin and paclitaxel (ABCP)
Autor:
Potprommanee, Laddawan, Ma, Haou-Tzong, Shank, Lalida, Juan, Yi-Hsiu, Liao, Wei-Yu, Chen, Shui-Tein, Yu, Chong-Jen
Publikováno v:
In Journal of Thoracic Oncology January 2015 10(1):102-109
Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer
Autor:
Lee, Jih-Hsiang, Lin, Yu-Lin, Hsu, Wei-Hsun, Chen, Hsuan-Yu, Chang, Yeun-Chung, Yu, Chong-Jen, Shih, Jin-Yuan, Lin, Chia-Chi, Chen, Kuan-Yu, Ho, Chao-Chi, Laio, Wei-Yu, Yang, Pan-Chyr, Yang, James Chih-Hsin
Publikováno v:
In Journal of Thoracic Oncology September 2014 9(9):1385-1392
Autor:
Fabrice Barlesi, C. Matheny, Julien Mazieres, Diego Cortinovis, Wei Yu, Marcus Ballinger, Keunchil Park, David R. Gandara, S. Gadgeel, Achim Rittmeyer, Toyoaki Hida
Publikováno v:
Journal of Thoracic Oncology. 16:140-150
Introduction The phase 2 POPLAR and phase 3 OAK studies of the anti–programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab in patients with previously treated advanced NSCLC revealed significant improvements in survival versus docetaxel (p =
Autor:
Chia Chi Hsu, Daniel Stetson, Wei-Yu Liao, Kenneth S. Thress, James Chih-Hsin Yang, Aleksandra Markovets, Bin-Chi Liao
Publikováno v:
Transl Lung Cancer Res
Introduction Osimertinib is the current recommended treatment for EGFR T790M–positive NSCLC after EGFR tyrosine kinase inhibitor therapy. However, resistance to osimertinib therapy is inevitably acquired after a period of effective treatment. We ha
Autor:
Yang, James Chih-Hsin, Shepherd, Frances A., Kim, Dong-Wan, Lee, Gyeong-Won, Lee, Jong Seok, Chang, Gee-Chen, Lee, Sung Sook, Wei, Yu-Feng, Lee, Yun Gyoo, Laus, Gianluca, Collins, Barbara, Pisetzky, Francesca, Horn, Leora
Publikováno v:
In Journal of Thoracic Oncology May 2019 14(5):933-939
Publikováno v:
Journal of Thoracic Oncology. 16:S444
Autor:
Julien Mazieres, Achim Rittmeyer, K. Park, Shirish M. Gadgeel, David R. Gandara, Diego Cortinovis, Fabrice Barlesi, Wei Yu, Toyoaki Hida, Marcus Ballinger, C. Matheny
Publikováno v:
Journal of Thoracic Oncology. 16:S15